Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Innate Pharma S.A. (NASDAQ: IPHA)
IPHA Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-22.10%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
205.40%
IPHA Stock Analysis
IPHA
PE Ratio:
IPHA
PEG Ratio:
Not Available
IPHA
Forward EPS Growth (12 month):
0.00%
IPHA
PS Ratio:
15.6
IPHA
PSG Ratio:
-1.1
IPHA
Forward Revenue Growth (12 month):
-14.20%
IPHA Articles
No data was found